Press Releases

 
Press Releases
  Date Title and Summary View
Jan 11, 2017
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Jan. 11, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's biologics license application (BLA) for MYL-1401O, a proposed biosimilar trastuzumab, for filing t...
Jan 9, 2017
HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that CEO Heather Bresch will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2017, in San Francisco. The presentation is scheduled to begin at 9:00 a.m. PST (12:00 p.m. EST). Interested p...
Jan 9, 2017
HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has agreed to acquire global rights to Cold-EEZE® brand cold remedy line from ProPhase Labs, Inc. The 20-year old Cold-EEZE® brand includes a family of leading over-the-counter (OTC) cold remedies currentl...
Dec 29, 2016
HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen's Concerta® Tablets.  Mylan received final approval from the U.S. Food and Drug Administr...
Dec 29, 2016
HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Fosphenytoin Sodium Injection USP, 75 mg/mL, (50 mg PE*/mL), packaged in 100 mg PE*/2 mL, and 500 mg PE*/10 mL single-use vials, a generic version of Pfizer's Cerebyx® Injection. Mylan received final approval ...
Dec 28, 2016
HERTFORDSHIRE, England and PITTSBURGH, Dec. 28, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP, 1 mg / 0.05 mg. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Zovia® 1/50E-...
Dec 27, 2016
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Dec. 27, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the results of the HERITAGE study have been published in the Journal of the American Medical Association (JAMA). Study results confirm the efficacy, safety and ...
Dec 16, 2016
HERTFORDSHIRE, England and PITTSBURGH, Dec. 16, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the launch of the authorized generic for EpiPen® (epinephrine injection, USP) Auto-Injector at a wholesale acquisition cost (WAC) of $300 per epinephrine injection, USP two-pack, which is more than 50% lower than the WAC of EpiPe...
Dec 1, 2016
HERTFORDSHIRE, England and PITTSBURGH, Dec. 1, 2016 /PRNewswire/ -- Today, Mylan N.V. (NASDAQ, TASE: MYL) joins people worldwide in recognizing World AIDS Day. Observed every Dec. 1, the occasion represents an opportunity to support people living with HIV/AIDS and to remember the approximately 35 million who have died from AIDS-related illnesses si...
Nov 28, 2016
HERTFORDSHIRE, England and BENGALURU, India, Nov. 28, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the company has signed an agreement with the Medicines Patent Pool (MPP) to expand access to chronic hepatitis C medicines in developing countries. The agreement licenses Mylan to produce and market a generic version of Bri...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase